Implementing SGLT2 Inhibitors in Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Multidisciplinary Expert Perspective.
Practical guidance helps doctors use a proven kidney-protective heart drug across multiple conditions affecting the same patients.
Multidisciplinary expert perspective consolidating guidance on SGLT2 inhibitor use across the cardiovascular-kidney-metabolic syndrome spectrum, addressing practical barriers to cross-specialty implementation. Actionable for clinicians managing patients with overlapping cardiometabolic conditions.
What the study was
- Study design
- Expert perspective/consensus review
- Population
- CKM syndrome patients across cardiology, nephrology, diabetology
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- European Heart Journal. Cardiovascular Pharmacotherapy
Why it surfaced
Practical expert guidance for SGLT2 implementation across CKM syndrome; directly actionable for multidisciplinary teams.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.